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Abstract
Background:  Correlations of disease phenotypes with glycosylation changes have been analysed
intensively in the tumor biology field. Glycoforms potentially associated with carcinogenesis, tumor
progression and cancer metastasis have been identified. In cancer therapy, drug resistance is a severe
problem, reducing therapeutic effect of drugs and adding to patient suffering. Although multiple
mechanisms likely underlie resistance of cancer cells to anticancer drugs, including overexpression of
transporters, the relationship of glycans to drug resistance is not well understood.
Results: We established epirubicin (EPI) – and mitoxantrone (MIT) – resistant cell lines (HLE-EPI and
HLE-MIT) from the human hepatocellular carcinoma cell line (HLE). HLE-EPI and HLE-MIT overexpressed
transporters MDR1/ABCB1 and BCRP/ABCG2, respectively. Here we compared the glycomics of HLE-
EPI and HLE-MIT cells with the parental HLE line. Core fucosylated triantennary oligosaccharides were
increased in the two resistant lines. We investigated mRNA levels of glycosyltransferases synthesizing this
oligosaccharide, namely, N-acetylglucosaminyltransferase (GnT)-IVa, GnT-IVb and α1,6-fucosyltransferase
(α1,6-FucT), and found that α1,6-FucT was particularly overexpressed in HLE-MIT cells. In HLE-EPI cells,
GnT-IVa expression was decreased, while GnT-IVb was increased. Both GnT-IVs were downregulated in
HLE-MIT cells. HLE-MIT cells also showed decreases in fucosylated tetraantennary oligosaccharide, the
product of GnT-V. GnT-V expression was decreased in both lines, but particularly so in HLE-MIT cells.
Thus both N-glycan and glycosyltransferase expression was altered as cells acquired tolerance, suggesting
novel mechanisms of drug resistance.
Conclusion: N-glycan and glycosyltransferase expression in HLE-EPI and HLE-MIT were analysed and
presented that glycans altered according with acquired tolerance. These results suggested novel
mechanisms of drug resistance.
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Background
Several chemotherapeutic agents are used to treat malig-
nant tumors. However, acquired resistance to these agents
frequently occurs and is a serious problem during treat-
ment. One cause of resistance is elevated expression or
activity of ATP-binding cassette (ABC) transporters, such
as multidrug resistant protein 1 (MDR1/ABCB1) and
breast cancer resistance protein (BCRP/ABCG2). Both
transporters are membrane glycoproteins containing N-
glycans.
Oligosaccharide expression is highly relevant to many
cancers. Many studies show that alterations in N-linked
oligosaccharides of tumor cells are associated with car-
cinogenesis, invasion and metastasis [1,2]. Yamashita et al
reported that products of N-acetylglucosaminyltransferase
(GnT)-IV, GnT-V and α1,6-fucosyltransferase (α1,6-FucT)
are all increased in hepatocellular carcinoma [3]. However
the relationship between chemoresistance and N-glycans
has been investigated in very few studies.
Asparagine (Asn) 596 of BCRP is normally glycosylated.
Studies in which this residue was mutated indicate that N-
glycosylation at Asn 596 is not essential for BCRP expres-
sion, trafficking to the plasma membrane, or function
[4,5]. On the other hand, a multi-drug-resistant cell line in
which MDR1 is highly expressed showed reduced toler-
ance following loss of MDR1 function and decreased gly-
cosylation mediated by tunicamycin, which inhibits
biosynthesis of glycan precursors [6].
A different study showed that the activity of β-galactoside
α2,6-sialyltransferase I in human colon cancer cells was
lost when they acquired methotrexate resistance and that
glycan structures on the cell membrane were altered [7].
N-linked glycans on α5β1 integrin in cisplatin-resistant
head and neck cancer cell showed reduced β1,6-N-
acetylglucosamine branches compared to the parent line
[8]. These studies have detected alterations in N-glycan
with lectins, but little information is still available on pre-
cise structural alteration of N-glycans in drug-resistant
cells.
Epirubicin (EPI) and mitoxantrone (MIT) are widely used
for cancer chemotherapy. We have established EPI-resist-
ant cells (HLE-EPI), which overexpress MDR1, and MIT-
resistant cells (HLE-MIT), which overexpress BCRP, from
HLE human hepatocellular carcinoma cells [9]. To detect
N-glycan structures that potentially underlie anticancer
drug resistance, we compared the glycomics of HLE, HLE-
EPI, and HLE-MIT lines. We also compared expression of
mRNA encoding glycosyltransferases involved in the syn-
thesis of glycans potentially mediating resistance in these
lines.
Results
Oligosaccharides detailed structures and ratios
Pyridylaminated (PA)-oligosaccharide samples of HLE,
HLE-EPI and HLE-MIT were separated and their elution
positions were analyzed on octadecylsilyl (ODS) columns
(Fig. 1). Separated sample peaks were analyzed on amide
columns, and structures of oligosaccharides contained in
each peak were determined using 2-dimensional mapping
(2-DM) strategies. Molar ratios of oligosaccharides were
calculated based on peak areas from the ODS analysis
(Table 1). Quantitative analysis of 9 peaks on the ODS
column showed that the level of one complex type oli-
gosaccharide [Galβ1,4-GlcNAcβ1,2-Manα1,6-(Galβ1,4-
GlcNAcβ1,4-(Galβ1,4-GlcNAcβ1,2-)Manα1,3-)Manβ1,4-
GlcNAcβ1,4-(Fucα1,6-)GlcNAc (code No: 310.8)], a tri-
antennary core-fucosylated oligosaccharide structure,
increased in drug-resistant cells, particularly HLE-MIT. We
then analyzed more detail ratios of complex type oligosac-
charides using further amide analysis (Fig. 2). Among
those oligosaccharides, only 310.8 increased in drug-
resistant cells. Levels of non-fucosylated triantennary oli-
gosaccharides (300.8) and biantennary oligosaccharides
(200.4 and 210.4) were unchanged in resistant cells, but
tetraantennary glycans (400.16 and 410.16) decreased in
HLE-MIT.
Expression of glycosyltransferases
The biosynthetic pathway of N-glycans shown in Figure 3
highlights importance of enzymes α1,6-FucT, GnT-IV and
GnT-V. We estimated the enzymatic activity of α1,6-FucT
from the ratio of core-fucosylated (210.4, 310.8, 410.16)
to non-fucosylated (200.4, 300.8, 400.16) oligosaccha-
rides, GnT-IV from triantennary plus tetraantennary
(300.8, 310.8, 400.16, 410.16)/biantennary (200.4,
210.4) oligosaccharides, and GnT-V from tetraantennary
(400.16, 410.16)/triantennary oligosaccharides (300.8,
310.8) (Fig 4). Estimated activities of α1,6-FucT and GnT-
IV were increased in drug resistant cells, while GnT-V was
decreased.
To analyze expression of these glycosyltransferases, RT-
PCR was performed (Fig 5). α1,6-FucT in HLE-EPI levels
were slightly decreased, and GnT-IVa in drug-resistant
cells was slightly increased; however, the difference
between parental and drug-resistant cells remained
unclear. We performed real-time RT-PCR analysis to con-
firm these results more quantitatively (Table 2). α1,6-
FucT expression was increased in drug-resistant cells, espe-
cially in HLE-MIT. GnT-IVa was decreased in drug-resist-
ant cells, but GnT-IVb was increased in HLE-EPI and
decreased in HLE-MIT lines. GnT-V was decreased in drug-
resistant cells.Molecular Cancer 2007, 6:32 http://www.molecular-cancer.com/content/6/1/32
Page 3 of 9
(page number not for citation purposes)
Chromatograms of PA-N-glycans identified on ODS columns Figure 1
Chromatograms of PA-N-glycans identified on ODS columns. Letters and asterisks over peaks correspond with Table 
1.Molecular Cancer 2007, 6:32 http://www.molecular-cancer.com/content/6/1/32
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Discussion
To elucidate the mechanism of drug resistance, we inves-
tigated N-glycans and glycosyltransferases in parental and
drug-resistant cells. The structures of fifteen types of oli-
gosaccharides were determined, and one in particular–
310.8–was dramatically increased in resistant cells. This
N-glycan is synthesized by GnT-IV and α1,6-FucT. We
examined expression of these two glycosyltransferases
together with GnT-V, which is reported to be associated
with cancer malignancy.
Both core α1,6-fucosylated N-glycans and α1,6-FucT
expression are associated with cancer. Fucosylation of
serum proteins has been reported as tumor marker on IgG
and  α-fetoprotein in hepatocellular carcinoma [10,11]
and haptoglobin in pancreatic cancer [12]. Our glycomic
analysis showed high core-fucosylation in both resistant
lines, and particularly high expression of α1,6-FucT in
HLE-MIT. These results support the idea that fucosylation
anomalies occur in cancer. Proteins such as IgG, α-feto-
protein and haptoglobin contain mainly biantennary N-
glycans. Here, we observed that only triantennary–not bi-
and tetraantennary–N-glycans were increased, although
we cannot as yet account for why these changes occur.
Alterations in core fucosylation are associated with
changes in protein function: fucose removal from oli-
gosaccharides of the scFv-Fc domain of human IgG1
results in significantly enhanced cellular cytotoxicity [13-
15]. In vivo, Wang showed that α1,6-FucT null mice
showed semi-lethality and severe growth retardation [16].
These mice also overexpressed matrix metalloproteinases-
12 and -13, an alteration associated with pathological
lung phenotypes including emphysema-like changes.
Nakagawa reported that this core α1,6-Fuc works as a sig-
nal of secreting carrier protein to bile ducts in a liver [17].
This core α1,6-Fuc is also essential for epidermal growth
factor function [18]. Thus, core α1,6-Fuc has critical func-
tions, and proteins bearing 310.8 are presumed to protect
cancer cells from anticancer drugs.
GnT-IV is a glycosyltransferase functioning in 310.8 syn-
thesis. GnT-IV activity is associated with metastasis of
colorectal carcinoma [19], is increased in choriocarci-
noma [20], and is decreased in renal cell carcinoma [21].
Human chorionic gonadotropins from patients with cho-
riocarcinoma contain oligosaccharides modified by GnT-
IV [22] and Ide et al investigated the relationship between
pancreatic cancer and GnT-IV [23]. From these results
show that GnT-IV functions are not inherently good or
bad in the context of cancer. Here, we show that GnT-IV
products increase in both resistant cells, but expression of
GnT-IVs were not correlated with products. Detailed oli-
gosaccharide structural analysis and evaluation of glyco-
syltransferase expression were not precisely correlating,
Alterations of complex type oligosaccharide ratios in cell  lines Figure 2
Alterations of complex type oligosaccharide ratios in 
cell lines. Ratios were calculated based on amide column 
isolation following separation using ODS columns.
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Table 1: N-Glycan ratios from HLE, HLE-EPI and HLE-MIT cells analyzed on ODS columns
Oligosaccharide Molar ratio(%)
HLE HLE-EPI HLE-MIT
a M8.1 15.06 16.12 18.48
b M7.2 + M9.1 26.83 21.02 24.77
c M7.1 5.63 7.88 3.95
d M6.1 6.45 7.80 8.29
e 010.0 + 010.1 16.56 14.07 12.70
f 200.4 + 400.16 4.11 2.59 2.91
g 300.8 4.77 4.57 3.34
h 210.4 + 410.16 14.57 14.67 11.58
i 310.8 6.01 11.29 13.97
* 300.18 Detected (< 1.00)
* * 310.18 Detected (<1.00)
Detailed structures are shown in Fig. 1 and code numbers of oligosaccharides follow the designations of Takahashi [36, 37].Molecular Cancer 2007, 6:32 http://www.molecular-cancer.com/content/6/1/32
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most likely because N-glycan biosynthesis depends on
several variables, including carrier protein character and
synthesis, a supply of sugar nucleotides, a precise enzyme
location, and degradation of enzyme and products. Such
a discrepancy suggests that both glycan profiles and
expression or activation of glycosyltransferases must be
defined.
GnT-V is reportedly an indicator of tumor malignancy
[24,25]. However Nakahara et al reported that GnT-V
activity was correlated with cisplatin sensitivity in squa-
mous cell carcinoma [8], and Ishimura showed that GnT-
V and its resultant β1,6-branched N-linked oligosaccha-
rides were closely related to low malignant potential and
good prognosis in bladder cancer patients [26]. In our
study, expression of GnT-V and glycomic analysis of the
tetraantennary (400.16, 410.16)/triantennary (300.8,
310.8) ratio suggested that GnT-V activity in drug-resist-
ant cells was lower than in parental cells. These findings
agree with Nakahara's and Ishimura's results that GnT-V
activity is not simply associated with outcomes such as
high grade malignancy, poor prognosis, or anticancer
drug resistance. N-glycan structures from the 3 cell lines
we examined were almost the same, which is natural
because the 2 drug-resistant cell lines were established
RT-PCR analysis of glycosyltransferase mRNA expression in  each cell line Figure 5
RT-PCR analysis of glycosyltransferase mRNA 
expression in each cell line. Detailed experimental proce-
dures are in Materials and Methods. Human glyceraldehyde-
3-phosphate dehydrogenase (hGAPDH) is reported for 
internal controls.
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Biosynthesis pathway of complex type N-glycans Figure 3
Biosynthesis pathway of complex type N-glycans. The 
reactions of α1,6-FucT, GnT-IV and GnT-V and complex 
type N-glycan structures in this study are highlighted. GnT-IV 
and GnT-V increase number of antenna, and some of them 
are modified by α1,6-FucT. Then, they are galactosylated by 
β1,4- galactosyltransferase as shown as black arrows. The 
products of GnT-V were modified by GnT-IV in this study, so 
we have indicated that GnT-V works after GnT-IV in the bio-
synthetic pathway. However, it is possible that GnT-V may 
act at an earlier step than GnT-IV.
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Glycosyltransferase activities estimated by ratios of N-glycans Figure 4
Glycosyltransferase activities estimated by ratios of 
N-glycans. Alpha1,6-FucT, (210.4+310.8+410.16)/
(200.4+300.8+400.16); GnT-IV, 
(300.8+310.8+400.16+410.16)/(200.4+210.4); and GnT-V, 
(400.16+410.16)/(300.8+310.8).
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from the same parental cell line. However, there were
some differences in N-glycan ratios and gene expression
between HLE-EPI and HLE-MIT. EPI and MIT have similar
structures and the same mechanism of cell toxicity: bind-
ing DNA and inhibiting topoisomerase II activity [27].
Nevertheless, EPI produces a hydroxyl radical but MIT
does not [28], and Moriyama reported that gene expres-
sion patterns in response to EPI and MIT differed [27]. In
addition, many mechanisms of drug resistance have been
reported even against the same reagents, so the differences
we saw between HLE-EPI and HLE-MIT are acceptable.
N-glycans bind proteins, and the combinations of glycan
and protein may be important in their function [1,2].
Despite many genomic and proteomic studies of drug
resistance [29,30], no dramatic change in the abundance
of a protein has been clearly associated with drug resist-
ance. It is more likely that the altered N-glycans we
observed bind various proteins, and that altered N-gly-
cans associated with several different proteins affect the
drug-resistance mechanisms.
The ABC transporter is a key factor in drug resistance. Our
cell lines overexpressed MDR1/ABCB1 (HLE-EPI) and
BCRP/ABCG2 (HLE-MIT). Previously, correlation
between N-glycan presence and transporter expression,
localization, and function were investigated [4-6,31].
However, there is no information concerning potential
direct effects on transporter activity by N-glycan struc-
tures, because these studies inhibited glycosylation either
by mutating N-glycan-bearing asparagine residues or by
tunicamycin treatment. Determination of N-glycan struc-
tures of transporters and whether transporter activity is
altered by changes in those structures is a topic for further
studies.
Conclusion
Here, we analyzed glycomics of HLE, HLE-EPI, and HLE-
MIT lines and detected quantitative changes in N-glycans,
that core-fucosylated triantennary N-glycans are clearly
increased in anticancer drug-resistant cells. Ours is the
first study identifying precise oligosaccharide structures
and related glycosyltransferase activities that may be
involved in anticancer drug resistance.
Methods
Chemicals
Trypsin and sodium cyanoborohydride were purchased
from Sigma-Aldrich Co. (St. Louis, MO), α-chymotrypsin
and pronase were from Calbiochem Co. (Darmstadt, Ger-
many), peptide-N-glycosidase F (PNGase F) was from
Hoffman-La Roche (Basel, Switzerland), glucose oligom-
ers (4 – 20) were from Seikagaku Co. (Tokyo, Japan), and
2-aminopyridine was from Wako Pure Chemicals (Osaka,
Japan). Bio-Gel P-4 (200–400 mesh) was obtained from
Bio-Rad Laboratories (Hercules, CA), Sephadex G-15
from Amersham Biosciences (Uppsala, Sweden), an octa-
decyl-bonded silica (ODS) column, ShimPack HRC-ODS,
(6.0 mm i.d. × 150 mm) from Shimadzu Co. (Kyoto,
Japan), and TSKgel Amide 80 column (Amide column)
(4.6 mm i.d. × 250 mm) from Tosoh (Tokyo, Japan). EPI
hydrochloride was obtained from Pfizer Japan Inc.
(Tokyo, Japan). MIT hydrochloride was purchased from
Sigma-Aldrich (St Louis, MO).
Cell lines and culture
HLE human hepatocellular carcinoma cells were pur-
chased from JCRB Cell Bank (Osaka, Japan). EPI-resistant
(HLE-EPI) and MIT-resistant (HLE-MIT) cells were estab-
lished from HLE as described [9]. Cells were cultured in
Dulbecco's modified Eagle medium with 10 % (v/v) fetal
Table 2: Glycosyltransferase gene expression analyzed quantitatively by real-time RT-PCR
Enzyme Cell line mRNA expression (ratio against HLE) S.D. p Value (vs HLE)
α1,6-FucT HLE 1.000 0.212 -
HLE-EPI 1.100 0.062 0.402
HLE-MIT 1.832 0.454 0.016
GnT-IVa HLE 1.000 0.136 -
HLE-EPI 0.037 0.005 7.897 × 10-6
HLE-MIT 0.003 0.001 6.421 × 10-6
GnT-IVb HLE 1.000 0.170 -
HLE-EPI 1.304 0.124 0.028
HLE-MIT 0.561 0.085 0.004
GnT-V HLE 1.000 0.428 -
HLE-EPI 0.302 0.105 0.019
HLE-MIT 0.122 0.044 0.006
mRNA expression is based on an average of 5 experiments. S.D.; standard deviation.Molecular Cancer 2007, 6:32 http://www.molecular-cancer.com/content/6/1/32
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bovine serum [32]. HLE-EPI or HLE-MIT cells were main-
tained by exposing them to the respective drugs at 32 ng/
ml for two days before passage. Cells were plated onto
100 mm culture dishes at a density of 1 × 106 cells/dish.
Twelve dishes per line were cultured simultaneously. Cells
were harvested using EDTA and trypsin and pelleted by
centrifugation.
Preparation and derivatization of N-linked 
oligosaccharide
Cells from four dishes were pooled to make one sample,
washed twice with phosphate buffered saline, resus-
pended in water, heated at 90°C for 15 min, and lyophi-
lized. Dried cells (approximately 5 mg each) were
digested with 50 μg each of trypsin and α-chymotrypsin,
and N-linked oligosaccharides were released from pep-
tides with 5 U of PNGase F. Peptides were then digested
with 50 μg pronase. Each step was done in 10 mmol/l
ammonium bicarbonate, pH 8.0, at 37°C overnight. Oli-
gosaccharides were purified on Bio-gel P-4 columns and
reductively aminated with 2-aminopyridine and sodium
cyanoborohydride [33,34]. PA-oligosaccharides were
purified by gel filtration on a Sephadex G-15 column (1.0
× 38 cm) with 10 mmol/l ammonium bicarbonate. To
release sialic acids, oligosaccharides were heated 1 h at
90°C at pH 2.0 (with HCl).
PA-oligosaccharide profiling by the 2-DM method using 
high performance liquid chromatography (HPLC)
PA-oligosaccharides were analyzed by the 2-DM method
using a Hitachi L-7000 HPLC system (Hitachi High-Tech-
nologies Co., Tokyo, Japan) [35,36]. PA-oligosaccharide
samples were first analyzed on an ODS column. Elution
was performed at a flow rate of 1.0 ml per minute at 55°C
using a gradient system. Solvent A was10 mmol/l sodium
phosphate buffer (pH 3.8) and solvent B was 0.5% (v/v)
1-butanol added in solvent A. The column was equili-
brated with solvent (A : B = 80 : 20 (v/v)), and then the
injection ratio of solvent B was increased linearly to 50 %
over 60 min. Eluted PA-oligosaccharides were detected
with a fluorescence spectrometer, and excitation and
emission wavelengths were 320 nm and 400 nm, respec-
tively. Separated oligosaccharides of each peak of the ODS
column were analyzed using an Amide column at a flow
rate of 1.0 ml per minute at 40°C with solvent C (3% (v/
v) acetic acid-triethylamine (pH 7.3)/acetonitrile 35 : 65)
and solvent D (3% (v/v) acetic acid-triethylamine (pH
7.3)/acetonitrile 50 :50). The column was initially equili-
brated with only solvent C, and elution was performed
using a linear gradient to solvent (C:D = 40:60 (v/v)) in 30
min. PA-oligosaccharides were also monitored by fluores-
cence. The elution position of PA-oligosaccharide on each
column was converted to glucose unit (GU) values to
make reproducibility. The relative amount of PA-oligosac-
charide was calculated based on the peak area analyzed by
software used in conjunction with the HPLC system. Oli-
gosaccharide structures were suggested by comparing elu-
tion positions with data reported in the same analytical
conditions [36,37]. Code numbers of oligosaccharide
structures described in this manuscript are according these
references.
Reverse transcription (RT)-polymerase chain reaction 
(PCR)
Total RNA was isolated from cultured cells with ISOGEN
(Nippon Gene, Tokyo, Japan) according to the manufac-
turer's protocol. 5 μg total RNA was used with ReverTra
Ace (Toyobo Co., Osaka, Japan) for reverse transcription.
The reaction mixture was according to the manufacturer's
protocol with 50 ng total RNA. Primer sequences were as
follows: 5'-CAGACAGATGGAGCAGGTGA-3' (forward)
and 5'-ACCACATGATGGAGCTGACA-3' (reverse) for
α1,6-fucosyltransferase (fucosyltransferase 8, α1,6-FucT);
5'-ACCAAGGGCATACGCTGGAG-3' (forward) and 5'-
GTTCTTGGTTGCCGCTATGGA-3' (reverse) for N-
acetylglucosaminyltransferase (GnT)-IVa; 5'-ACTTCATC-
CGCTTCCGCTTC-3' (forward) and 5'-TCCTTGTCTGACT-
GAGGGTTGT-3' (reverse) for GnT-IVb; 5'-
CTCAGCGCCCTACAGGTCAA-3' (forward) and 5'-CTT-
GATGAAGTCCCGGCAGG-3' (reverse) for GnT-V; and 5'-
GCCTCCTGCACCACCTG-3' (forward) and 5'-
CGACGCCTGCTTCACCACCTTCT-3' (reverse) for
GAPDH. Product sizes of α1,6-FucT, GnT-IVa, GnT-IVb,
GnT-V and GAPDH were 170 bp, 144 bp, 142 bp, 291 bp
and 351 bp, respectively.
PCR was performed using the Expand High Fidelity PCR
System (Roche, Basel, Switzerland). PCR cycles started
with 2 min at 94°C and then 35 cycles of 15 sec at 94°C,
30 sec at 56°C, and 30 sec at 72°C for α1,6-FucT and
GAPDH; 45 cycles of 15 sec at 94°C, 30 sec at 60°C and
30 sec at 72°C for GnT-IVa, GnT-IVb and GnT-V. PCR
products were electrophoresed on 1.5% agarose gels and
stained with ethidium bromide.
mRNA quantification
Real-time RT-PCR was performed using a LightCycler™
(Roche) with a QuantiTect SYBR Green PCR Kit (QIAGEN
K.K., Tokyo, Japan). Reaction mixtures were made accord-
ing to the manufacturer's instruction with 50 ng total
RNA. Primer sequences were the same as for RT-PCR.
Real-time PCR cycles started with 15 min at 95°C and
then 45 cycles of 15 sec at 94°C, 20 sec at 56°C and 20 sec
at 72°C for α1,6-FucT; 50 cycles of 15 sec at 94°C, 20 sec
at 60°C and 15 sec at 72°C for GnT-IVa and GnT-IVb; 50
cycles of 15 sec at 94°C, 20 sec at 60°C and 25 sec at 72°C
for GnT-V; and 45 cycles of 15 sec at 94°C, 20 sec at 56°C
and 20 sec at 72°C for GAPDH. Expression levels of α1,6-
FucT, GnT-IVa, GnT-IVb, and GnT-V were expressed as
ratios relative to GAPDH.Molecular Cancer 2007, 6:32 http://www.molecular-cancer.com/content/6/1/32
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